0001209191-17-053158.txt : 20170918 0001209191-17-053158.hdr.sgml : 20170918 20170918163533 ACCESSION NUMBER: 0001209191-17-053158 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170914 FILED AS OF DATE: 20170918 DATE AS OF CHANGE: 20170918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RITTER DALE CENTRAL INDEX KEY: 0001244154 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36829 FILM NUMBER: 171090201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INOTEK PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001281895 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 91 HARTWELL AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-676-2100 MAIL ADDRESS: STREET 1: 91 HARTWELL AVE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-14 0 0001281895 INOTEK PHARMACEUTICALS CORP ITEK 0001244154 RITTER DALE C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE 2ND FLOOR LEXINGTON MA 02421 0 1 0 0 Vice President, Finance Common Stock 2017-09-14 4 M 0 12500 0.00 A 19827 D Restricted Stock Units 2017-01-17 4 M 0 12500 0.00 D Common Stock 12500 37500 D Includes 7,327 shares of ITEK's common stock acquired under ITEK's Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 with Table I information. Of these 7,237 shares of ITEK's common stock, 2,591 shares were acquired on November 30, 2015 at the price of $4.83, 782 shares were acquired on May 31, 2016 at the price of $7.82, 1,765 shares were acquired on November 30, 2016 at the price of $5.44 and 2,189 shares were acquired on May 31, 2017 at the price of $1.45. On September 14, 2017, 12,500 shares of Common Stock were issued in settlement of the restricted stock units described in footnote (4) below. Each restricted stock unit represents a contingent right to receive one share of ITEK common stock. The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). The restricted stock units vest in equal 25% tranches every 6 months over a 2 year period from the date of grant, subject to continued service through such dates. /s/ Dale Ritter 2017-09-18